23 February 2023 in Phenomics
Immunophenotyping is proving crucial to understanding the role of the immune system in health and disease. High-throughput flow cytometry has been used extensively to reveal changes in immune cell composition and function at the single-cell level. Here, we describe six optimized 11-color flow cytometry panels for deep immunophenotyping of human whole blood. A total of 51 surface antibodies, which are readily available and validated, were selected to identify the key immune cell populations and evaluate their functional state in a single assay. The gating strategies for effective flow cytometry data analysis are included in the protocol. To ensure data reproducibility, we provide detailed procedures in three parts, including (1) instrument characterization and detector gain optimization, (2) antibody titration and sample staining, and (3) data acquisition and quality checks. This standardized approach has been applied to a variety of donors for a better understanding of the complexity of the human immune system.
10 February 2025 in Nature Communications
Genomic structural variants (SVs) are a major source of genetic diversity in humans. Here, through long-read sequencing of 945 Han Chinese genomes, we identify 111,288 SVs, including 24.56% unreported variants, many with predicted functional importance. By integrating human population-level phenotypic and multi-omics data as well as two humanized mouse models, we demonstrate the causal roles of two SVs: one SV that emerges at the common ancestor of modern humans, Neanderthals, and Denisovans in GSDMD for bone mineral density and one modern-human-specific SV in WWP2 impacting height, weight, fat, craniofacial phenotypes and immunity. Our results suggest that the GSDMD SV could serve as a rapid and cost-effective biomarker for assessing the risk of cisplatin-induced acute kidney injury. The functional conservation from human to mouse and widespread signals of positive natural selection suggest that both SVs likely influence local adaptation, phenotypic diversity, and disease susceptibility across diverse human populations.
12 September 2023 in Phenomics
1 January 2026 in Hypertension
BACKGROUND: Myocardial infarction (MI)–induced ischemia leads to abnormal ventricular remodeling and cardiac fibrosis, which can ultimately progress to heart failure. Kif23 (kinesin-like protein 23) has been implicated in the progression of various diseases. This study aims to investigate the role of Kif23 in the development of cardiac fibrosis following MI. METHODS: Male C57BL/6J mice received intravenous injections of adeno-associated virus carrying Kif23 shRNA, followed by left anterior descending coronary artery ligation to induce MI. Cardiac function and fibrosis were assessed via echocardiography, histological analysis, and fibrosis marker quantification at 7 and 14 days post-MI. In vitro, adult rat cardiac fibroblasts underwent Kif23 knockdown or overexpression, with subsequent TGF-β1 (Transforming Growth Factor Beta 1) treatment. Proteomic profiling, lipid droplet analysis, and fibrosis/lipid metabolism assessments were performed. RESULTS: Kif23 expression was significantly upregulated in both infarcted myocardium and TGF-β1–stimulated adult rat cardiac fibroblasts. Kif23 knockdown improved cardiac function and attenuated fibrosis post-MI. In vitro, Kif23 silencing suppressed fibroblast proliferation and myofibroblast transdifferentiation, whereas Kif23 overexpression potentiated fibrotic responses. Proteomic profiling identified Ces1d (carboxylesterase 1d) as a key downstream effector upregulated by Kif23 knockdown, concomitant with restored fatty acid β-oxidation. Mechanistically, Kif23 impairs Ces1d-mediated fatty acid β-oxidation via RhoA (Ras Homolog Family Member A)/ROCK1 (Rho-associated protein kinase 1) signaling, driving fibrosis progression. CONCLUSIONS: Our study identifies Kif23 as a novel regulator of post-MI cardiac fibrosis. Mechanistically, Kif23 drives fibroblast proliferation through RhoA activation and exacerbates fibrogenesis by suppressing Ces1d-dependent fatty acid β-oxidation via the RhoA/ROCK1 axis. This metabolic disruption triggers pathological lipid accumulation and myofibroblast transdifferentiation. These findings nominate Kif23 as a promising therapeutic target for antifibrotic interventions.